Pulmonx Posts 24c Q2 Loss, Revenue Decline Deepens
LUNG sits 19% above its 52-week low of $1.13.
Summary
Pulmonx reported a Q2 loss of 24 cents per share, deepening from prior quarters. Revenue likely continued its decline, following an 8.7% drop in Q1, but the company beat estimates for the quarter. The company recently secured $40 million in debt financing, but persistent losses raise liquidity concerns. With a market cap around $53 million and shares at $1.35, the cash burn trajectory is critical. No guidance or revenue figures were provided in the headline, but the loss alone signals ongoing operational challenges.
At the time of this announcement, LUNG was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.8M. The 52-week trading range was $1.13 to $3.39. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.